December 4, 2017 — Fujifilm Medical Systems U.S.A. Inc. announced the expansion of the company's artificial intelligence (AI) development initiative with entry in the U.S. market. The AI development initiative will harness the power of AI to enhance Fujifilm’s imaging and informatics healthcare Synapse portfolio which includes Synapse PACS (picture archiving and communication system), Synapse Cardiovascular and Synapse VNA (vendor neutral archive), among other solutions. The initiative was on display at the 2017 Radiological Society of North America (RSNA) annual meeting, Nov. 26-Dec. 1 in Chicago.
The program will be based in Raleigh, N.C., the global development headquarters for Fujifilm's Synapse portfolio, in collaboration with Fujifilm Corp.'s development team in Tokyo that will provide a wide range of image recognition technologies. Fujifilm will partner with its strategic customers in the U.S. market, to draw upon clinical insights and expertise in the field to bridge AI applications to imaging informatics solutions.
For more information: www.fujimed.com
March 30, 2026 
